|
1
|
Rakha EA, Reis-Filho JS, Baehner F, Dabbs
DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani
SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, Tse
GM, Badve S and Ellis IO: Breast cancer prognostic classification
in the molecular era: the role of histological grade. Breast Cancer
Res. 12:2072010.
|
|
2
|
Fuksa L, Micuda S, Grim J, Ryska A and
Hornychova H: Predictive biomarkers in breast cancer: their value
in neoadjuvant chemotherapy. Cancer Invest. 30:663–678. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thibault C, Khodari W, Lequoy M, Gligorov
J and Belkacémi Y: HER2 status for prognosis and prediction of
treatment efficacy in adenocarcinomas: A review. Crit Rev Oncol
Hematol. 88:123–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Metzger-Filho O, Tutt A, de Azambuja E,
Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis
P, Di Leo A, Baselga J, Sotiriou C and Piccart-Gebhart M:
Dissecting the heterogeneity of triple-negative breast cancer. J
Clin Oncol. 30:1879–1887. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ford D, Easton DF, Stratton M, Narod S,
Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J,
Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J,
Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch
H, Ponder BA, Gayther SA, Zelada-Hedman M, et al: Genetic
heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes
in breast cancer families. The Breast Cancer Linkage Consortium. Am
J Hum Genet. 62:676–689. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dent R and Warner E: Screening for
hereditary breast cancer. Semin Oncol. 34:392–400. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meads C, Ahmed I and Riley RD: A
systematic review of breast cancer incidence risk prediction models
with meta-analysis of their performance. Breast Cancer Res Treat.
132:365–377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peshkin BN, Alabek ML and Isaacs C:
BRCA1/2 mutations and triple negative breast cancers. Breast Dis.
32:25–33. 2010.PubMed/NCBI
|
|
10
|
Meyer P, Landgraf K, Högel B, Eiermann W
and Ataseven B: BRCA2 mutations and triple-negative breast cancer.
PLoS One. 7:e383612012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Budroni M, Cesaraccio R, Pirino D, Sechi
O, Oggiano M, Piras D, Sechi A, Cossu A, Palmieri G and Tanda F:
Cancer incidence in Sassari Province (1998–2002). Cancer Incidence
in Five Continents. IXCurado MP, Edwards B, Shin HR, Storm H,
Ferlay J, Heanue M and Boyle P: (International Agency for Research
on Cancer (IARC) Scientific Publications). (160)Lyon: IARC; pp.
331–332. 2007
|
|
12
|
Palomba G, Pisano M, Cossu A, Budroni M,
Dedola MF, Farris A, Contu A, Baldinu P, Tanda F and Palmieri G:
Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in
Sardinian breast cancer patients through a hospital-based
screening. Cancer. 104:1172–1179. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Palomba G, Cossu A, Friedman E, Budroni M,
Farris A, Contu A, Pisano M, Baldinu P, Sini MC, Tanda F and
Palmieri G: Origin and distribution of the BRCA2-8765delAG mutation
in breast cancer. BMC Cancer. 7:1322007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Palomba G, Loi A, Uras A, Fancello P,
Piras G, Gabbas A, Cossu A, Budroni M, Contu A, Tanda F, Farris A,
Orrù S, Floris C, Pisano M, Lovicu M, Santona MC, Landriscina G,
Crisponi L, Palmieri G and Monne M: A role of BRCA1 and BRCA2
germline mutations in breast cancer susceptibility within Sardinian
population. BMC Cancer. 9:2452009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wright AF, Carothers AD and Pirastu M:
Population choice in mapping genes for complex diseases. Nat Genet.
23:397–404. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arcos-Burgos M and Muenke M: Genetics of
population isolates. Clin Genet. 61:233–247. 2002. View Article : Google Scholar
|
|
17
|
Mote PA, Leary JA, Avery KA, Sandelin K,
Chenevix-Trench G, Kirk JA and Clarke CL; kConFab Investigators.
Germ-line mutations in BRCA1 or BRCA2 in the normal breast are
associated with altered expression of estrogen-responsive proteins
and the predominance of progesterone receptor A. Genes Chromosomes
Cancer. 39:236–248. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Veronesi A, de Giacomi C, Magri MD,
Lombardi D, Zanetti M, Scuderi C, Dolcetti R, Viel A, Crivellari D,
Bidoli E and Boiocchi M: Familial breast cancer: characteristics
and outcome of BRCA 1–2 positive and negative cases. BMC Cancer.
5:702005.
|
|
19
|
Musolino A, Bella MA, Bortesi B, Michiara
M, Naldi N, Zanelli P, Capelletti M, Pezzuolo D, Camisa R, Savi M,
Neri TM and Ardizzoni A: BRCA mutations, molecular markers, and
clinical variables in early-onset breast cancer: a population-based
study. Breast. 16:280–292. 2007. View Article : Google Scholar
|
|
20
|
Casula M, Colombino M, Satta MP, Cossu A,
Lissia A, Budroni M, Simeone E, Calemma R, Loddo C, Caracò C,
Mozzillo N, Daponte A, Comella G, Canzanella S, Guida M, Castello
G, Ascierto PA and Palmieri G; Italian Melanoma Intergroup. Factors
predicting the occurrence of germline mutations in candidate genes
among patients with cutaneous malignant melanoma from South Italy.
Eur J Cancer. 43:137–143. 2007. View Article : Google Scholar
|
|
21
|
Palomba G, Colombino M, Contu A, Massidda
B, Baldino G, Pazzola A, Ionta MT, Capelli F, Trova V, Sedda T,
Sanna G, Tanda F and Budroni M; Sardinian Translational Oncology
Group (STOG). Palmieri G, Cossu A, Contu M, Cuccu A, Farris A,
Macciò A, Mameli G, Olmeo N, Ortu S, Petretto E, Pusceddu V and
Virdis L: Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in
patients with colorectal carcinoma may vary in the same population:
clues from Sardinia. J Transl Med. 10:1782012. View Article : Google Scholar
|
